The North America ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 12.5% during the forecast period, 2018 to 2023. The United States is expected to dominate the market for ovarian cancer diagnostics and therapeutics due to the increasing incidence of ovarian cancer.
The risk of ovarian cancer increases in women in the age bracket of 55-64 years. According to the US Census Bureau, women above 60 years of age accounted for almost 57% of all ovarian cancer incidences and 75% of all ovarian cancer related deaths worldwide, with median age at diagnosis being 63 years and median age at death being 70 years. Thus, the increasing population of aged women is driving the growth of the North American ovarian cancer diagnostics and therapeutics market.
In addition, the increasing incidence of ovarian cancer worldwide and greater use of combination therapies for the treatment of ovarian cancer are fueling the growth of the North American ovarian cancer diagnostics and therapeutics market.
Accurate diagnosis for ovarian cancer is critical, as in most cases, the cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early stage 1 detection is 93%, and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often because ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. In addition, patent expiry of key drugs is also restraining the growth of the market.
The United States is dominating the market due to increasing incidence of ovarian cancer. As per the American Cancer Society, it was estimated that 22,280 new cases of ovarian cancer would be diagnosed in 2017, whereas in 2016, an estimated 20,000 patients were diagnosed with ovarian cancer in the United States alone.
The major players include - Bristol Myers Squibb Company, Eli Lilly and Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Genentech Inc., Astra Zeneca Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, among others.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 Increasing Incidences of Ovarian Cancer Worldwide
6.1.2 Increasing Population of Aged Women
6.1.3 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer
6.2 Market Restraint
6.2.1 Patent Expiry of Key Drugs
6.2.2 Lack of Accurate Diagnosis of Ovarian Cancer
6.4 Key Challenges
7. Market Segmentation
7.1 By Cancer Type
7.1.1 Epithelial Ovarian Tumors
7.1.2 Ovarian Germ Cell Tumors
7.1.3 Ovarian Stromal Tumors
7.1.4 Primary Peritoneal Carcinoma
7.2 By Cancer Stage
7.2.1 Stage I
7.2.2 Stage II
7.2.3 Stage III
7.3 By Diagnosis
7.3.1 Physical Examination
7.3.3 Blood Tests
7.3.4 Human Chorionic Gonadotropin (HCG) Test
7.3.7 CT Scan
7.4 By Treatment
7.4.2 Targeted Therapy
7.4.3 Radiation Therapy
7.4.5 Hormonal Therapy
7.5 By Geography
7.5.1 North America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Astra Zeneca
9.2 Boehringer Ingelheim
9.3 Bristol Myers Squibb Company
9.4 Eli Lilly and Company
9.5 F. Hoffman-La Roche Ltd
9.6 Genentech Inc.
9.7 Glaxosmithkline Plc
9.8 Janssen Pharmaceuticals, Inc.
*List Not Exhausitive
10. Outlook of the Market